|
|
|
Substance Name: Lansoprazole [USAN:USP:INN:BAN]
RN: 103577-45-3
UNII: 0K5C5T2QPG
InChIKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N
Note
- A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Molecular Formula
- C16-H14-F3-N3-O2-S
Molecular Weight
- 369.366
Classification Codes
- Anti-Infective Agents
- Anti-Ulcer Agents
- Anti-Ulcerative
- Antiviral (COVID-19)
- Drug / Therapeutic Agent
- Enzyme Inhibitors
- Gastrointestinal Agents
- Proton Pump Inhibitors
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Lansoprazole
- Lansoprazole [USAN:USP:INN:BAN]
MeSH Heading
- Lansoprazole
Synonyms
- 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
- A 65006
- A-65006
- AG 1749
- AG-1749
- Agopton
- Amarin
- Aprazol
- Bamalite
- Blason
- BRN 4333393
- Compraz
- Dakar
- HSDB 7204
- Ilsatec
- Ketian
- Lancid
- Lanproton
- Lansopep
- Lansoprazol
- Lansoprazol [INN-Spanish]
- Lansoprazole
- Lansoprazolum
- Lansoprazolum [INN-Latin]
- Lanston
- Lanz
- Lanzol-30
- Lanzopral
- Lanzor
- Lasoprol
- Limpidex
- Mesactol
- Monolitum
- NSC 758638
- Ogastro
- Opiren
- Prevacid
- Prevacid 24HR
- Prevacid I.V.
- Prevacid IV
- Prevacid SoluTab
- Prezal
- Pro Ulco
- Promp
- Prosogan
- Suprecid
- TAK 390MR
- TAK-390MR
- Takepron
- Ulpax
- UNII-0K5C5T2QPG
- Zoprol
- Zoton
Systematic Name
- 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
Registry Numbers
CAS Registry Number
- 103577-45-3
FDA UNII
- 0K5C5T2QPG
System Generated Number
- 0103577453
Structure Descriptors
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)InChIKey
MJIHNNLFOKEZEW-UHFFFAOYSA-NSmiles
Cc1c(OCC(F)Toxicity
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD | oral | > 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 387, 1993. | |
| mouse | LD50 | intraperitoneal | > 5gm/kg (5000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
| mouse | LD50 | oral | > 5gm/kg (5000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
| mouse | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, | |
| mouse | LDLo | intravenous | 75mg/kg (75mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996. |
| rat | LD50 | intraperitoneal | 5gm/kg (5000mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, |
| rat | LD50 | oral | > 5gm/kg (5000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, | |
| rat | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl, | |
| rat | LDLo | intravenous | 58mg/kg (58mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: ATAXIA | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996. |